Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DDSW97
|
|||
Drug Name |
Camonsertib
|
|||
Synonyms |
Camonsertib; RP-3500; RP3500; 2417489-10-0; camonsertib [INN]; Camonsertib [USAN]; Camonsertib (RP-3500); ATR inhibitor 4;Camonsertib; S1Z7Y5G56T; CHEMBL5095260; SCHEMBL23515008; SCHEMBL23515085; GTPL12073; RP 3500 [WHO-DD]; Rp 3500; 8-Oxabicyclo[3.2.1]octan-3-ol, 3-[6-[(3R)-3-methyl-4-morpholinyl]-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-, (3-endo)-; EX-A6416; NSC841442; NSC-841442; MS-27079; CS-0226170; F83116; (1R,3r,5S)-3-{6-[(3R)-3-methylmorpholin-4-yl]-1-(1Hpyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl}-8-oxabicyclo[3.2.1]octan-3-ol; (1R,3R,5S)-3-6-[(3R)-3-methylmorpholin-4-yl]-1-(1Hpyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl-8-oxabicyclo[3.2.1]octan-3-ol; (1R,5S)-3-[6-[(3R)-3-methylmorpholin-4-yl]-1-(1H-pyrazol-5-yl)pyrazolo[3,4-b]pyridin-4-yl]-8-oxabicyclo[3.2.1]octan-3-ol
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1/2 | [1] | |
Company |
Roche
|
|||
Structure |
Download2D MOL |
|||
Formula |
C21H26N6O3
|
|||
Canonical SMILES |
CC1COCCN1C2=NC3=C(C=NN3C4=CC=NN4)C(=C2)C5(CC6CCC(C5)O6)O
|
|||
InChI |
InChI=1S/C21H26N6O3/c1-13-12-29-7-6-26(13)19-8-17(21(28)9-14-2-3-15(10-21)30-14)16-11-23-27(20(16)24-19)18-4-5-22-25-18/h4-5,8,11,13-15,28H,2-3,6-7,9-10,12H2,1H3,(H,22,25)/t13-,14-,15+,21?/m1/s1
|
|||
InChIKey |
YIHHYCIYAIVQKX-YNOVCBQDSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Serine/threonine-protein kinase ATR (FRP1) | Target Info | Inhibitor | [2] |
KEGG Pathway | Fanconi anemia pathway | |||
Cell cycle | ||||
p53 signaling pathway | ||||
HTLV-I infection | ||||
Panther Pathway | p53 pathway | |||
p53 pathway feedback loops 2 | ||||
Pathway Interaction Database | Fanconi anemia pathway | |||
ATR signaling pathway | ||||
Signaling events mediated by TCPTP | ||||
Circadian rhythm pathway | ||||
BARD1 signaling events | ||||
p53 pathway | ||||
Reactome | Meiotic synapsis | |||
Activation of ATR in response to replication stress | ||||
Regulation of HSF1-mediated heat shock response | ||||
HDR through Single Strand Annealing (SSA) | ||||
Processing of DNA double-strand break ends | ||||
Presynaptic phase of homologous DNA pairing and strand exchange | ||||
G2/M DNA damage checkpoint | ||||
WikiPathways | DNA Damage Response | |||
Meiotic Synapsis | ||||
Prostate Cancer | ||||
Integrated Breast Cancer Pathway | ||||
Integrated Cancer pathway | ||||
Cell Cycle | ||||
Cell Cycle Checkpoints | ||||
miRNA Regulation of DNA Damage Response |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04972110) Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC). U.S.National Institutes of Health. | |||
REF 2 | Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.